Quest Diagnostics Q4 Adjusted EPS $2.15 Beats $2.11 Estimate, Sales $2.29B Beat $2.25B Estimate
Portfolio Pulse from Benzinga Newsdesk
Quest Diagnostics (NYSE:DGX) reported Q4 adjusted EPS of $2.15, surpassing the $2.11 estimate, and sales of $2.29B, exceeding the $2.25B estimate. This represents an 8.59% increase in EPS and a 1.93% decrease in sales from the same period last year.
February 01, 2024 | 11:49 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Quest Diagnostics reported a strong Q4 with EPS of $2.15, beating estimates, and sales of $2.29B, also above expectations. Despite a slight sales decrease from last year, earnings grew by 8.59%.
The positive earnings report, with both earnings per share and sales beating estimates, indicates a strong financial performance by Quest Diagnostics. The growth in earnings per share, despite a slight decrease in sales, suggests operational efficiency and could lead to positive investor sentiment in the short term. The direct beat on both top and bottom lines is a bullish signal for the stock.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100